Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — AstraZeneca said Friday that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors, a result that could limit the use of the … [Read more…]
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. How much time does Mark … [Read more…]
Over the past few years, many researchers have tried to test large language models’ medical capabilities using questions from the U.S. medical licensure exam, or by feeding them clinical vignettes containing a set amount of information about a given case. Other researchers have called for an end to those exercises, saying that these examples are … [Read more…]
There are stories that stand out as remarkable testaments to the power of perseverance, innovation, and family values in any industry, including the business of construction and design. Mark Wanner’s journey from an Amish upbringing to the visionary founder of KRÄM Construction & Design encapsulates all these elements and more. This is a tale of … [Read more…]